行情

PTN

PTN

PALATIN TECH
AMEX

实时行情|Nasdaq Last Sale

0.7913
+0.0213
+2.77%
盘后: 0.7900 -0.0013 -0.16% 17:31 11/15 EST
开盘
0.7700
昨收
0.7700
最高
0.8000
最低
0.7500
成交量
127.63万
成交额
--
52周最高
1.780
52周最低
0.5900
市值
1.80亿
市盈率(TTM)
6.13
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTN 新闻

  • 花旗策略师:美股明年面临四大障碍
  • 新浪美股.5小时前
  • 三大指数提供商最快在12月将沙特阿美纳入其指数
  • 新浪美股.6小时前
  • 日韩企业联手 韩媒:将对阿里腾讯构成巨大威胁
  • 参考消息.8小时前
  • 外媒:流媒体平台如何改变人们看电视的方式
  • 参考消息.8小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

PTN 简况

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
展开

Webull提供Palatin Technologies, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。